Venrock

Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease primarily affecting boys. The company's lead product candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in patients' muscles. In addition to SGT-001, Solid Biosciences is advancing the Anti-LTBP4 program, which involves a monoclonal antibody designed to reduce fibrosis and inflammation by targeting the LTBP4 protein. The company also develops biomarkers and sensors, as well as the Solid Suit program, which focuses on creating wearable assistive devices with functional and therapeutic benefits. Founded in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences has established a strategic collaboration with Ultragenyx to enhance gene therapy development for DMD. With no current cure for DMD, the company aims to provide innovative solutions for a condition that affects an estimated 10,000 to 15,000 cases in the United States.

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for eye diseases using its proprietary bioresorbable hydrogel platform technology. The company markets ReSure Sealant, a hydrogel ophthalmic wound sealant designed to protect corneal incisions after cataract surgery. Its lead product candidate, DEXTENZA, is an ophthalmic insert that has completed Phase III clinical trials for post-surgical ocular pain, inflammation, and allergic conjunctivitis, and is also being investigated for dry eye diseases. Additionally, Ocular Therapeutix is developing several other products, including OTX-TP, an intracanalicular travoprost insert for glaucoma, and OTX-TKI, an intravitreal implant for wet age-related macular degeneration, among others. The company has established a strategic collaboration with Regeneron Pharmaceuticals to leverage its hydrogel technology in combination with Regeneron's VEGF-targeting compounds for retinal diseases. Founded in 2006 and headquartered in Bedford, Massachusetts, Ocular Therapeutix aims to address unmet needs in ophthalmology through its advanced therapeutic solutions.

Astria Therapeutics is a biopharmaceutical company focused on developing therapies for rare and niche allergic and immunological diseases. It is advancing monoclonal antibody programs such as STAR-0215, a plasma kallikrein inhibitor being developed for hereditary angioedema, and STAR-0310, an OX40 antagonist for atopic dermatitis, both in preclinical development to address immune-mediated inflammatory conditions.

Tisento Therapeutics, based in Massachusetts, specializes in developing innovative medicines to address diseases with substantial unmet medical needs. Its primary focus is on Mitochondrial Encephalomyopathy with Lactic Acidosis and Stroke (MELAS), a severe mitochondrial disorder. The company's therapies aim to treat mitochondrial diseases, both in the central nervous system and peripherally, by targeting key aspects of the disease's pathophysiology, including neuronal and mitochondrial function, cerebrovascular hemodynamics, and inflammatory processes. This approach enables patients to receive treatment promptly.

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, established in 2011. The company specializes in the development and commercialization of Haduvio, an oral extended-release formulation of nalbuphine. Haduvio is currently undergoing a Phase IIb/III clinical trial, known as the PRISM trial, aimed at treating chronic pruritus associated with prurigo nodularis. Additionally, Trevi is exploring the use of nalbuphine ER for other serious neurologically mediated conditions, including chronic cough in patients with idiopathic pulmonary fibrosis and levodopa-induced dyskinesia in individuals with Parkinson’s disease. The treatment targets conditions that share a common pathophysiology mediated through opioid receptors in the central and peripheral nervous systems.

Cyteir Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing innovative therapies based on DNA repair biology for cancer treatment and synthetic lethality in autoimmune diseases. Founded in 2012 and headquartered in Lexington, Massachusetts, the company focuses on precision targeting of critical DNA repair factors to induce self-destruction in diseased cells through an overload of DNA damage. Cyteir employs an integrated drug development platform that addresses the imbalance between DNA damage and repair, resulting in a pipeline of small molecule therapeutics aimed at various disease states, including hematological malignancies, solid tumors, and chronic autoimmune disorders. Its lead compound, CYT-0851, is an oral investigational drug designed to inhibit RAD51-mediated homologous recombination, targeting specific vulnerabilities in cancer cells.

Mable is a Boston-based company that operates a mobile and web-based B2B wholesale e-commerce platform specifically designed for retailers and distributors in the grocery sector. Founded in 2019, the platform enables users to discover and purchase a diverse range of products from various brands, including Black Dinah Chocolatiers, Brave Coffee & Tea, Coastal Craft Kombucha, Crown Maple, Eddie's Bakery, Loco Coffee, Real Food Bar, and STOKES Firestarters. Mable aims to streamline the wholesale buying process, providing an efficient solution for grocers seeking to source quality products.

Salsify is an e-commerce software startup based in Boston, Massachusetts, founded in 2012 by Jason Purcell, Jeremy Redburn, and Rob Gonzalez. The company provides a comprehensive platform known as Commerce Experience Management (CommerceXM), which integrates Product Experience Management tools—including Product Information Management (PIM), Digital Asset Management (DAM), and an Experience Builder—with essential commerce functionalities. This platform is designed to facilitate sales across various channels, including retailers, distributors, marketplaces, social commerce, and direct-to-consumer (D2C) sites. By offering these tools, Salsify aims to enhance brand visibility and performance on digital shelves, helping businesses optimize their product presentation and inventory management to drive online sales effectively.

Surface Oncology, Inc. is a clinical-stage immuno-oncology company based in Cambridge, Massachusetts, focused on developing innovative cancer therapies. The company specializes in creating human immunoglobulin isotype G4 monoclonal antibodies, including SRF231, which inhibits CD47; NZV930, which targets CD73; SRF617, which inhibits CD39; SRF388, aimed at interleukin 27; and SRF813, which targets CD112R. Additionally, Surface Oncology is advancing several preclinical programs that address other critical elements of the tumor microenvironment, such as regulatory T cells and natural killer cells. The company has established strategic collaborations with Novartis Institutes for Biomedical Research and Merck Sharp & Dohme Corp. to advance the development of its therapies, including evaluating the combination of SRF617 with Merck’s KEYTRUDA. Founded in 2014, Surface Oncology aims to leverage novel immunotherapy targets and insights into cancer immuno-biology to enhance anti-tumor immune responses.

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Lexington, Massachusetts, dedicated to the discovery, development, and commercialization of innovative treatments for hematological and musculoskeletal disorders with significant unmet medical needs. The company's lead product candidate, KER-050, targets low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes and myelofibrosis. Additionally, Keros is developing KER-047, a small molecule aimed at treating anemia and fibrodysplasia ossificans progressiva, which is currently in Phase 1 clinical trials. Another candidate, KER-012, is being explored for its potential in treating bone loss disorders such as osteoporosis and osteogenesis imperfecta, as well as pulmonary arterial hypertension. Keros Therapeutics emphasizes understanding the role of the Transforming Growth Factor-Beta family of proteins, which are crucial for the regulation of blood cell production and the maintenance of muscle and bone health.

Kyruus, Inc. is a Boston-based company that develops web-based software solutions aimed at optimizing physician networks for hospitals, health systems, and life science companies. Founded in 2010, Kyruus offers a suite of analytically driven products designed to enhance provider search and scheduling, ensuring that patients are matched with the most suitable healthcare providers. Key offerings include Kyruus Passport, which allows physicians to track their activity and productivity, and Kyruus Profiles, which enables administrators to analyze physician performance metrics. Additionally, the company provides Kyruus MDSeekyr, a platform for identifying high-value providers, and Kyruus Insight Reports, which help executives evaluate network activity and performance trends. By leveraging a proprietary provider data management platform, Kyruus enhances patient engagement and aligns provider supply with patient demand, ultimately improving the overall healthcare experience. Kyruus also maintains offices in San Francisco and New York.

Mable is a Boston-based company that operates a mobile and web-based B2B wholesale e-commerce platform specifically designed for retailers and distributors in the grocery sector. Founded in 2019, the platform enables users to discover and purchase a diverse range of products from various brands, including Black Dinah Chocolatiers, Brave Coffee & Tea, Coastal Craft Kombucha, Crown Maple, Eddie's Bakery, Loco Coffee, Real Food Bar, and STOKES Firestarters. Mable aims to streamline the wholesale buying process, providing an efficient solution for grocers seeking to source quality products.

Cyteir Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing innovative therapies based on DNA repair biology for cancer treatment and synthetic lethality in autoimmune diseases. Founded in 2012 and headquartered in Lexington, Massachusetts, the company focuses on precision targeting of critical DNA repair factors to induce self-destruction in diseased cells through an overload of DNA damage. Cyteir employs an integrated drug development platform that addresses the imbalance between DNA damage and repair, resulting in a pipeline of small molecule therapeutics aimed at various disease states, including hematological malignancies, solid tumors, and chronic autoimmune disorders. Its lead compound, CYT-0851, is an oral investigational drug designed to inhibit RAD51-mediated homologous recombination, targeting specific vulnerabilities in cancer cells.

Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative therapeutics for unmet medical needs in cancer treatment. The company specializes in the field of epigenetics, aiming to address cancers associated with abnormal gene expression and drug resistance. Its lead product candidates include CPI-0610, which is undergoing Phase II clinical trials for myelofibrosis in combination with ruxolitinib, and CPI-1205, currently in Phase Ib/II trials for metastatic castration-resistant prostate cancer in conjunction with androgen receptor signaling inhibitors. Additionally, Constellation is developing CPI-0209, which is in the Phase I dose escalation stage of a Phase I/II trial aimed at treating solid tumors. Founded in 2008, the company was previously known as Epigenetix, Inc. before rebranding to its current name in March 2008.

Sojournix Inc., established in 2016 and headquartered in Waltham, Massachusetts, is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for women's health and neuroendocrine disorders. Its primary focus is SJX-653, a selective neurokinin-3 (NK3) antagonist, designed as a non-hormonal treatment option for moderate to severe vasomotor symptoms associated with menopause.

Salsify is an e-commerce software startup based in Boston, Massachusetts, founded in 2012 by Jason Purcell, Jeremy Redburn, and Rob Gonzalez. The company provides a comprehensive platform known as Commerce Experience Management (CommerceXM), which integrates Product Experience Management tools—including Product Information Management (PIM), Digital Asset Management (DAM), and an Experience Builder—with essential commerce functionalities. This platform is designed to facilitate sales across various channels, including retailers, distributors, marketplaces, social commerce, and direct-to-consumer (D2C) sites. By offering these tools, Salsify aims to enhance brand visibility and performance on digital shelves, helping businesses optimize their product presentation and inventory management to drive online sales effectively.

Corvidia Therapeutics, Inc. is a biotechnology company based in Waltham, Massachusetts, that specializes in developing precision therapies for cardiovascular and renal diseases. Founded in 2014, the company focuses on researching and commercializing innovative treatments aimed at addressing chronic kidney disease, particularly in patients with atherosclerotic cardiovascular disease and inflammation, as well as conditions like high triglyceride-induced acute pancreatitis. Corvidia Therapeutics is recognized for its approach that targets specific biologic pathways, enabling healthcare providers to deliver more effective therapies to patients with unique sensitivities. As of July 2020, Corvidia operates as a subsidiary of Novo Nordisk A/S.

Kyruus, Inc. is a Boston-based company that develops web-based software solutions aimed at optimizing physician networks for hospitals, health systems, and life science companies. Founded in 2010, Kyruus offers a suite of analytically driven products designed to enhance provider search and scheduling, ensuring that patients are matched with the most suitable healthcare providers. Key offerings include Kyruus Passport, which allows physicians to track their activity and productivity, and Kyruus Profiles, which enables administrators to analyze physician performance metrics. Additionally, the company provides Kyruus MDSeekyr, a platform for identifying high-value providers, and Kyruus Insight Reports, which help executives evaluate network activity and performance trends. By leveraging a proprietary provider data management platform, Kyruus enhances patient engagement and aligns provider supply with patient demand, ultimately improving the overall healthcare experience. Kyruus also maintains offices in San Francisco and New York.

Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative therapeutics for unmet medical needs in cancer treatment. The company specializes in the field of epigenetics, aiming to address cancers associated with abnormal gene expression and drug resistance. Its lead product candidates include CPI-0610, which is undergoing Phase II clinical trials for myelofibrosis in combination with ruxolitinib, and CPI-1205, currently in Phase Ib/II trials for metastatic castration-resistant prostate cancer in conjunction with androgen receptor signaling inhibitors. Additionally, Constellation is developing CPI-0209, which is in the Phase I dose escalation stage of a Phase I/II trial aimed at treating solid tumors. Founded in 2008, the company was previously known as Epigenetix, Inc. before rebranding to its current name in March 2008.

Cyteir Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing innovative therapies based on DNA repair biology for cancer treatment and synthetic lethality in autoimmune diseases. Founded in 2012 and headquartered in Lexington, Massachusetts, the company focuses on precision targeting of critical DNA repair factors to induce self-destruction in diseased cells through an overload of DNA damage. Cyteir employs an integrated drug development platform that addresses the imbalance between DNA damage and repair, resulting in a pipeline of small molecule therapeutics aimed at various disease states, including hematological malignancies, solid tumors, and chronic autoimmune disorders. Its lead compound, CYT-0851, is an oral investigational drug designed to inhibit RAD51-mediated homologous recombination, targeting specific vulnerabilities in cancer cells.

Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative therapeutics for unmet medical needs in cancer treatment. The company specializes in the field of epigenetics, aiming to address cancers associated with abnormal gene expression and drug resistance. Its lead product candidates include CPI-0610, which is undergoing Phase II clinical trials for myelofibrosis in combination with ruxolitinib, and CPI-1205, currently in Phase Ib/II trials for metastatic castration-resistant prostate cancer in conjunction with androgen receptor signaling inhibitors. Additionally, Constellation is developing CPI-0209, which is in the Phase I dose escalation stage of a Phase I/II trial aimed at treating solid tumors. Founded in 2008, the company was previously known as Epigenetix, Inc. before rebranding to its current name in March 2008.

Salsify is an e-commerce software startup based in Boston, Massachusetts, founded in 2012 by Jason Purcell, Jeremy Redburn, and Rob Gonzalez. The company provides a comprehensive platform known as Commerce Experience Management (CommerceXM), which integrates Product Experience Management tools—including Product Information Management (PIM), Digital Asset Management (DAM), and an Experience Builder—with essential commerce functionalities. This platform is designed to facilitate sales across various channels, including retailers, distributors, marketplaces, social commerce, and direct-to-consumer (D2C) sites. By offering these tools, Salsify aims to enhance brand visibility and performance on digital shelves, helping businesses optimize their product presentation and inventory management to drive online sales effectively.

Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative therapeutics for unmet medical needs in cancer treatment. The company specializes in the field of epigenetics, aiming to address cancers associated with abnormal gene expression and drug resistance. Its lead product candidates include CPI-0610, which is undergoing Phase II clinical trials for myelofibrosis in combination with ruxolitinib, and CPI-1205, currently in Phase Ib/II trials for metastatic castration-resistant prostate cancer in conjunction with androgen receptor signaling inhibitors. Additionally, Constellation is developing CPI-0209, which is in the Phase I dose escalation stage of a Phase I/II trial aimed at treating solid tumors. Founded in 2008, the company was previously known as Epigenetix, Inc. before rebranding to its current name in March 2008.

Narvii creates a mobile community platform for long-tail interests, organizations, and brands. It specializes in the fields of enterprise applications, enterprise software, and mobile apps. It was founded in 2009 and is based in Medford, Massachusetts.

Kyruus, Inc. is a Boston-based company that develops web-based software solutions aimed at optimizing physician networks for hospitals, health systems, and life science companies. Founded in 2010, Kyruus offers a suite of analytically driven products designed to enhance provider search and scheduling, ensuring that patients are matched with the most suitable healthcare providers. Key offerings include Kyruus Passport, which allows physicians to track their activity and productivity, and Kyruus Profiles, which enables administrators to analyze physician performance metrics. Additionally, the company provides Kyruus MDSeekyr, a platform for identifying high-value providers, and Kyruus Insight Reports, which help executives evaluate network activity and performance trends. By leveraging a proprietary provider data management platform, Kyruus enhances patient engagement and aligns provider supply with patient demand, ultimately improving the overall healthcare experience. Kyruus also maintains offices in San Francisco and New York.

KalVista Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing small molecule protease inhibitors for diseases with unmet needs. Its primary focus is on hereditary angioedema (HAE) and diabetic macular edema (DME). The company's product portfolio includes KVD001, KVD900, and KVD824, which are in various stages of clinical trials for treating these conditions.

Salsify is an e-commerce software startup based in Boston, Massachusetts, founded in 2012 by Jason Purcell, Jeremy Redburn, and Rob Gonzalez. The company provides a comprehensive platform known as Commerce Experience Management (CommerceXM), which integrates Product Experience Management tools—including Product Information Management (PIM), Digital Asset Management (DAM), and an Experience Builder—with essential commerce functionalities. This platform is designed to facilitate sales across various channels, including retailers, distributors, marketplaces, social commerce, and direct-to-consumer (D2C) sites. By offering these tools, Salsify aims to enhance brand visibility and performance on digital shelves, helping businesses optimize their product presentation and inventory management to drive online sales effectively.

Happier develops a mobile application that helps users collect daily happy moments and share them with close friends and family, promoting positive reflection and social connection. The company also provides a learning platform to improve employees’ emotional fitness, offering tools to cultivate moments of joy, kindness, and meaning in daily life and a framework for organizations to support wellbeing. Based in Boston, Happier aims to inspire healthier habits through combining personal happiness practices with workplace wellness resources.

Gazelle is an e-commerce platform focused on the buying and selling of used electronic devices, including smartphones, tablets, laptops, and desktops. Founded in 2006 and headquartered in Boston, Massachusetts, with operations in Louisville, Kentucky, the company offers consumers an easy way to acquire cost-effective electronic gadgets. Gazelle pays cash for pre-owned devices, which it inspects and certifies before reselling them to customers. This process not only provides a convenient option for consumers looking to stay connected but also promotes the recycling of electronic gadgets, contributing to sustainability in the technology sector.

Mevion Medical Systems, Inc. is a company specializing in the development of proton therapy systems for cancer treatment. Founded in 2004 and headquartered in Littleton, Massachusetts, Mevion has established itself as a leader in the radiation therapy sector by creating innovative and effective solutions that enhance cancer care. The company, formerly known as Still River Systems, transitioned to its current name in 2011. Its flagship product, the MEVION S250 Proton Therapy System, aims to combine the advantages of traditional proton therapy with reduced size, cost, and complexity. This advancement enhances beam reliability and system uptime, making proton therapy more accessible and economically viable for cancer centers worldwide. Mevion operates internationally, with additional offices in the United Kingdom, China, and Japan, serving a global clientele.

Kwicr, formerly known as Q Factor, has developed the world's first mobile delivery network that enhances content delivery to mobile devices. This innovative network employs dynamic packet recovery technology to streamline the transmission of information, ensuring that applications maintain high performance even in challenging connectivity conditions. By addressing the critical need for speed and responsiveness, Kwicr enables developers to enhance their apps for iOS and Android, thereby improving user experiences across various sectors, including gaming, streaming video, and mobile enterprise applications. Additionally, Kwicr offers advanced analytics that provide developers with insights into speed, concurrent connections, and user engagement metrics. The company, based in Waltham, Massachusetts, operates on a cloud-based model with variable pricing, including a free version, making its services accessible to a wide range of developers. Kwicr is privately held and has secured venture capital funding from Sigma Prime and Venrock.

Mevion Medical Systems, Inc. is a company specializing in the development of proton therapy systems for cancer treatment. Founded in 2004 and headquartered in Littleton, Massachusetts, Mevion has established itself as a leader in the radiation therapy sector by creating innovative and effective solutions that enhance cancer care. The company, formerly known as Still River Systems, transitioned to its current name in 2011. Its flagship product, the MEVION S250 Proton Therapy System, aims to combine the advantages of traditional proton therapy with reduced size, cost, and complexity. This advancement enhances beam reliability and system uptime, making proton therapy more accessible and economically viable for cancer centers worldwide. Mevion operates internationally, with additional offices in the United Kingdom, China, and Japan, serving a global clientele.

Kyruus, Inc. is a Boston-based company that develops web-based software solutions aimed at optimizing physician networks for hospitals, health systems, and life science companies. Founded in 2010, Kyruus offers a suite of analytically driven products designed to enhance provider search and scheduling, ensuring that patients are matched with the most suitable healthcare providers. Key offerings include Kyruus Passport, which allows physicians to track their activity and productivity, and Kyruus Profiles, which enables administrators to analyze physician performance metrics. Additionally, the company provides Kyruus MDSeekyr, a platform for identifying high-value providers, and Kyruus Insight Reports, which help executives evaluate network activity and performance trends. By leveraging a proprietary provider data management platform, Kyruus enhances patient engagement and aligns provider supply with patient demand, ultimately improving the overall healthcare experience. Kyruus also maintains offices in San Francisco and New York.

Intarcia Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for chronic conditions requiring long-term treatment. The company is known for its innovative drug delivery platform, DUROS, which stabilizes and administers therapeutic proteins and peptides effectively. Among its key products is ITCA 650, currently in phase 3 clinical trials for type 2 diabetes, designed to provide patients with continuous dosing of an incretin mimetic therapy. Intarcia also explores treatments for obesity and other chronic disorders. Established in 1995 and headquartered in Boston, Massachusetts, Intarcia operates a manufacturing facility in Hayward, California, and a research and development center in Durham, North Carolina. The company was previously known as BioMedicines, Inc. before adopting its current name in 2004.

Intarcia Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for chronic conditions requiring long-term treatment. The company is known for its innovative drug delivery platform, DUROS, which stabilizes and administers therapeutic proteins and peptides effectively. Among its key products is ITCA 650, currently in phase 3 clinical trials for type 2 diabetes, designed to provide patients with continuous dosing of an incretin mimetic therapy. Intarcia also explores treatments for obesity and other chronic disorders. Established in 1995 and headquartered in Boston, Massachusetts, Intarcia operates a manufacturing facility in Hayward, California, and a research and development center in Durham, North Carolina. The company was previously known as BioMedicines, Inc. before adopting its current name in 2004.

Mevion Medical Systems, Inc. is a company specializing in the development of proton therapy systems for cancer treatment. Founded in 2004 and headquartered in Littleton, Massachusetts, Mevion has established itself as a leader in the radiation therapy sector by creating innovative and effective solutions that enhance cancer care. The company, formerly known as Still River Systems, transitioned to its current name in 2011. Its flagship product, the MEVION S250 Proton Therapy System, aims to combine the advantages of traditional proton therapy with reduced size, cost, and complexity. This advancement enhances beam reliability and system uptime, making proton therapy more accessible and economically viable for cancer centers worldwide. Mevion operates internationally, with additional offices in the United Kingdom, China, and Japan, serving a global clientele.

Gazelle is an e-commerce platform focused on the buying and selling of used electronic devices, including smartphones, tablets, laptops, and desktops. Founded in 2006 and headquartered in Boston, Massachusetts, with operations in Louisville, Kentucky, the company offers consumers an easy way to acquire cost-effective electronic gadgets. Gazelle pays cash for pre-owned devices, which it inspects and certifies before reselling them to customers. This process not only provides a convenient option for consumers looking to stay connected but also promotes the recycling of electronic gadgets, contributing to sustainability in the technology sector.

Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative therapeutics for unmet medical needs in cancer treatment. The company specializes in the field of epigenetics, aiming to address cancers associated with abnormal gene expression and drug resistance. Its lead product candidates include CPI-0610, which is undergoing Phase II clinical trials for myelofibrosis in combination with ruxolitinib, and CPI-1205, currently in Phase Ib/II trials for metastatic castration-resistant prostate cancer in conjunction with androgen receptor signaling inhibitors. Additionally, Constellation is developing CPI-0209, which is in the Phase I dose escalation stage of a Phase I/II trial aimed at treating solid tumors. Founded in 2008, the company was previously known as Epigenetix, Inc. before rebranding to its current name in March 2008.

Kyruus, Inc. is a Boston-based company that develops web-based software solutions aimed at optimizing physician networks for hospitals, health systems, and life science companies. Founded in 2010, Kyruus offers a suite of analytically driven products designed to enhance provider search and scheduling, ensuring that patients are matched with the most suitable healthcare providers. Key offerings include Kyruus Passport, which allows physicians to track their activity and productivity, and Kyruus Profiles, which enables administrators to analyze physician performance metrics. Additionally, the company provides Kyruus MDSeekyr, a platform for identifying high-value providers, and Kyruus Insight Reports, which help executives evaluate network activity and performance trends. By leveraging a proprietary provider data management platform, Kyruus enhances patient engagement and aligns provider supply with patient demand, ultimately improving the overall healthcare experience. Kyruus also maintains offices in San Francisco and New York.

Intarcia Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for chronic conditions requiring long-term treatment. The company is known for its innovative drug delivery platform, DUROS, which stabilizes and administers therapeutic proteins and peptides effectively. Among its key products is ITCA 650, currently in phase 3 clinical trials for type 2 diabetes, designed to provide patients with continuous dosing of an incretin mimetic therapy. Intarcia also explores treatments for obesity and other chronic disorders. Established in 1995 and headquartered in Boston, Massachusetts, Intarcia operates a manufacturing facility in Hayward, California, and a research and development center in Durham, North Carolina. The company was previously known as BioMedicines, Inc. before adopting its current name in 2004.

Gazelle is an e-commerce platform focused on the buying and selling of used electronic devices, including smartphones, tablets, laptops, and desktops. Founded in 2006 and headquartered in Boston, Massachusetts, with operations in Louisville, Kentucky, the company offers consumers an easy way to acquire cost-effective electronic gadgets. Gazelle pays cash for pre-owned devices, which it inspects and certifies before reselling them to customers. This process not only provides a convenient option for consumers looking to stay connected but also promotes the recycling of electronic gadgets, contributing to sustainability in the technology sector.

Acceleron Pharma is a biopharmaceutical company based in Cambridge, Massachusetts, founded in 2003. It specializes in discovering, developing, and commercializing therapeutics to treat serious and rare diseases. Acceleron's portfolio includes luspatercept-aamt, marketed as REBLOZYL for treating anemia in adult patients with beta-thalassemia, and also under investigation for myelodysplastic syndromes and myelofibrosis. Additionally, the company is developing Sotatercept for pulmonary arterial hypertension and ACE-083 for Charcot-Marie-Tooth disease. Acceleron's research focuses on growth and differentiation factors that regulate cellular proliferation, differentiation, and survival in various tissue types. The company collaborates with other organizations to advance its therapeutic candidates.

Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative therapeutics for unmet medical needs in cancer treatment. The company specializes in the field of epigenetics, aiming to address cancers associated with abnormal gene expression and drug resistance. Its lead product candidates include CPI-0610, which is undergoing Phase II clinical trials for myelofibrosis in combination with ruxolitinib, and CPI-1205, currently in Phase Ib/II trials for metastatic castration-resistant prostate cancer in conjunction with androgen receptor signaling inhibitors. Additionally, Constellation is developing CPI-0209, which is in the Phase I dose escalation stage of a Phase I/II trial aimed at treating solid tumors. Founded in 2008, the company was previously known as Epigenetix, Inc. before rebranding to its current name in March 2008.

Virdante Pharmaceuticals, established in 2007 and headquartered in Cambridge, Massachusetts, specializes in developing and marketing drugs targeting autoimmune and inflammatory diseases. Its product portfolio comprises antibody and Fc-fusion drugs designed to address these conditions.

Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative therapeutics for unmet medical needs in cancer treatment. The company specializes in the field of epigenetics, aiming to address cancers associated with abnormal gene expression and drug resistance. Its lead product candidates include CPI-0610, which is undergoing Phase II clinical trials for myelofibrosis in combination with ruxolitinib, and CPI-1205, currently in Phase Ib/II trials for metastatic castration-resistant prostate cancer in conjunction with androgen receptor signaling inhibitors. Additionally, Constellation is developing CPI-0209, which is in the Phase I dose escalation stage of a Phase I/II trial aimed at treating solid tumors. Founded in 2008, the company was previously known as Epigenetix, Inc. before rebranding to its current name in March 2008.

Cygilant is a Boston-based company that specializes in providing comprehensive cybersecurity solutions to mid-sized enterprises worldwide. Founded in 2001, the company designs and develops software platforms that offer real-time security monitoring, compliance automation, and threat detection services. Cygilant's flagship product, SecureVue, provides a unified situational awareness platform that delivers accurate insights into an organization's security posture via a single console. The company also offers cloud-based patch management solutions and professional services such as customer support and training. Cygilant operates with a strategic partnership with Qualys, Inc., and has additional offices in Burlington, Massachusetts, and Vancouver, Canada, along with a security operations center in Belfast, Northern Ireland.

Mevion Medical Systems, Inc. is a company specializing in the development of proton therapy systems for cancer treatment. Founded in 2004 and headquartered in Littleton, Massachusetts, Mevion has established itself as a leader in the radiation therapy sector by creating innovative and effective solutions that enhance cancer care. The company, formerly known as Still River Systems, transitioned to its current name in 2011. Its flagship product, the MEVION S250 Proton Therapy System, aims to combine the advantages of traditional proton therapy with reduced size, cost, and complexity. This advancement enhances beam reliability and system uptime, making proton therapy more accessible and economically viable for cancer centers worldwide. Mevion operates internationally, with additional offices in the United Kingdom, China, and Japan, serving a global clientele.

Gazelle is an e-commerce platform focused on the buying and selling of used electronic devices, including smartphones, tablets, laptops, and desktops. Founded in 2006 and headquartered in Boston, Massachusetts, with operations in Louisville, Kentucky, the company offers consumers an easy way to acquire cost-effective electronic gadgets. Gazelle pays cash for pre-owned devices, which it inspects and certifies before reselling them to customers. This process not only provides a convenient option for consumers looking to stay connected but also promotes the recycling of electronic gadgets, contributing to sustainability in the technology sector.

Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative therapeutics for unmet medical needs in cancer treatment. The company specializes in the field of epigenetics, aiming to address cancers associated with abnormal gene expression and drug resistance. Its lead product candidates include CPI-0610, which is undergoing Phase II clinical trials for myelofibrosis in combination with ruxolitinib, and CPI-1205, currently in Phase Ib/II trials for metastatic castration-resistant prostate cancer in conjunction with androgen receptor signaling inhibitors. Additionally, Constellation is developing CPI-0209, which is in the Phase I dose escalation stage of a Phase I/II trial aimed at treating solid tumors. Founded in 2008, the company was previously known as Epigenetix, Inc. before rebranding to its current name in March 2008.

Digit Wireless, operates as a user interface innovation company. It offers Fastap keypad technology solutions that enable to discover, access, and use messaging, mobile data, and voice services. The company licenses its technology to mobile manufacturers and operators. Digit Wireless, Inc. was founded in 2000 and is headquartered in Burlington, Massachusetts with additional offices in Beijing, Shanghai, Hong Kong, London, and Seoul.

Gazelle is an e-commerce platform focused on the buying and selling of used electronic devices, including smartphones, tablets, laptops, and desktops. Founded in 2006 and headquartered in Boston, Massachusetts, with operations in Louisville, Kentucky, the company offers consumers an easy way to acquire cost-effective electronic gadgets. Gazelle pays cash for pre-owned devices, which it inspects and certifies before reselling them to customers. This process not only provides a convenient option for consumers looking to stay connected but also promotes the recycling of electronic gadgets, contributing to sustainability in the technology sector.

Mevion Medical Systems, Inc. is a company specializing in the development of proton therapy systems for cancer treatment. Founded in 2004 and headquartered in Littleton, Massachusetts, Mevion has established itself as a leader in the radiation therapy sector by creating innovative and effective solutions that enhance cancer care. The company, formerly known as Still River Systems, transitioned to its current name in 2011. Its flagship product, the MEVION S250 Proton Therapy System, aims to combine the advantages of traditional proton therapy with reduced size, cost, and complexity. This advancement enhances beam reliability and system uptime, making proton therapy more accessible and economically viable for cancer centers worldwide. Mevion operates internationally, with additional offices in the United Kingdom, China, and Japan, serving a global clientele.

Acceleron Pharma is a biopharmaceutical company based in Cambridge, Massachusetts, founded in 2003. It specializes in discovering, developing, and commercializing therapeutics to treat serious and rare diseases. Acceleron's portfolio includes luspatercept-aamt, marketed as REBLOZYL for treating anemia in adult patients with beta-thalassemia, and also under investigation for myelodysplastic syndromes and myelofibrosis. Additionally, the company is developing Sotatercept for pulmonary arterial hypertension and ACE-083 for Charcot-Marie-Tooth disease. Acceleron's research focuses on growth and differentiation factors that regulate cellular proliferation, differentiation, and survival in various tissue types. The company collaborates with other organizations to advance its therapeutic candidates.

Adnexus, a Bristol-Myers Squibb R&D Company, specializes in the discovery and development of Adnectins, a unique class of targeted biologics. These proteins are engineered to block or stimulate therapeutic targets to combat various diseases, addressing significant medical needs in oncology, immunology, and cardiovascular health. Utilizing a proprietary protein engineering system known as PROfusion™, Adnexus can generate a vast library of over 10 trillion potential Adnectins. This technology enhances the efficiency of identifying candidates with desirable therapeutic properties. Among its product candidates is Angiocept/CT-322, an anti-angiogenesis agent aimed at treating cancer by inhibiting the VEGFR-2 pathway. Since its acquisition by Bristol-Myers Squibb in 2007, Adnexus has further advanced its capabilities in developing innovative medicines to improve patient outcomes.

AVEO Oncology is a biopharmaceutical company that specializes in developing and commercializing targeted therapies for oncology and other unmet medical needs. The company is known for its lead product, FOTIVDA (tivozanib), an oral vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor used in the treatment of renal cell carcinoma (RCC). AVEO has completed a Phase III trial for tivozanib and is exploring its use in combination with the immune checkpoint inhibitor Opdivo. Additionally, the company is developing other therapeutic candidates, including Ficlatuzumab, an antibody for various cancers, and AV-203, a monoclonal antibody for esophageal cancer, which has completed Phase I trials. AVEO's preclinical pipeline includes promising products aimed at treating conditions such as cachexia and pulmonary arterial hypertension. Headquartered in Boston, Massachusetts, the company was founded in 2001 and has established collaborations with various pharmaceutical firms to enhance its development efforts.

Intarcia Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for chronic conditions requiring long-term treatment. The company is known for its innovative drug delivery platform, DUROS, which stabilizes and administers therapeutic proteins and peptides effectively. Among its key products is ITCA 650, currently in phase 3 clinical trials for type 2 diabetes, designed to provide patients with continuous dosing of an incretin mimetic therapy. Intarcia also explores treatments for obesity and other chronic disorders. Established in 1995 and headquartered in Boston, Massachusetts, Intarcia operates a manufacturing facility in Hayward, California, and a research and development center in Durham, North Carolina. The company was previously known as BioMedicines, Inc. before adopting its current name in 2004.

Ironwood Pharmaceuticals is a specialty pharmaceutical company focused on gastroenterology therapies. Its lead product is linaclotide, marketed as LINZESS in the United States and CONSTELLA elsewhere, for adults with irritable bowel syndrome with constipation and chronic idiopathic constipation. The company is advancing other GI candidates, including MD-7246, an oral non-opioid pain reliever for abdominal GI pain, and IW 3718, a gastric-retentive bile acid sequestrant in Phase III for GERD. Ironwood pursues collaborations to expand linaclotide’s reach in North America, China, Hong Kong, Macau, and Japan, with agreements involving Allergan and AstraZeneca and a license with Astellas for Japan. It operates an independent subsidiary, Microbia, that develops bioprocesses for pharmaceuticals and related industries. Founded in 1998, Ironwood is headquartered in Massachusetts.

Magen BioSciences is a biotechnology company based in Waltham, Massachusetts, specializing in the development of pharmaceutical products aimed at enhancing human skin health. The company employs a science-driven methodology that is rooted in a comprehensive understanding of both normal and diseased skin biology. By leveraging this expertise, Magen BioSciences creates innovative solutions designed to improve the health and appearance of skin, addressing various dermatological needs.

Acceleron Pharma is a biopharmaceutical company based in Cambridge, Massachusetts, founded in 2003. It specializes in discovering, developing, and commercializing therapeutics to treat serious and rare diseases. Acceleron's portfolio includes luspatercept-aamt, marketed as REBLOZYL for treating anemia in adult patients with beta-thalassemia, and also under investigation for myelodysplastic syndromes and myelofibrosis. Additionally, the company is developing Sotatercept for pulmonary arterial hypertension and ACE-083 for Charcot-Marie-Tooth disease. Acceleron's research focuses on growth and differentiation factors that regulate cellular proliferation, differentiation, and survival in various tissue types. The company collaborates with other organizations to advance its therapeutic candidates.

Adnexus, a Bristol-Myers Squibb R&D Company, specializes in the discovery and development of Adnectins, a unique class of targeted biologics. These proteins are engineered to block or stimulate therapeutic targets to combat various diseases, addressing significant medical needs in oncology, immunology, and cardiovascular health. Utilizing a proprietary protein engineering system known as PROfusion™, Adnexus can generate a vast library of over 10 trillion potential Adnectins. This technology enhances the efficiency of identifying candidates with desirable therapeutic properties. Among its product candidates is Angiocept/CT-322, an anti-angiogenesis agent aimed at treating cancer by inhibiting the VEGFR-2 pathway. Since its acquisition by Bristol-Myers Squibb in 2007, Adnexus has further advanced its capabilities in developing innovative medicines to improve patient outcomes.

Everypoint Inc. provides solutions for developing and delivering mobile applications. It offers Nemo, a mobile application ecosystem that enables vector graphics, push notification, synchronization, and content delivery services on mass-market mobile applications and devices. The company offers its products to application developers. Everypoint Inc. was incorporated in 2002 and is based in Boston, Massachusetts.

Ironwood Pharmaceuticals is a specialty pharmaceutical company focused on gastroenterology therapies. Its lead product is linaclotide, marketed as LINZESS in the United States and CONSTELLA elsewhere, for adults with irritable bowel syndrome with constipation and chronic idiopathic constipation. The company is advancing other GI candidates, including MD-7246, an oral non-opioid pain reliever for abdominal GI pain, and IW 3718, a gastric-retentive bile acid sequestrant in Phase III for GERD. Ironwood pursues collaborations to expand linaclotide’s reach in North America, China, Hong Kong, Macau, and Japan, with agreements involving Allergan and AstraZeneca and a license with Astellas for Japan. It operates an independent subsidiary, Microbia, that develops bioprocesses for pharmaceuticals and related industries. Founded in 1998, Ironwood is headquartered in Massachusetts.

AVEO Oncology is a biopharmaceutical company that specializes in developing and commercializing targeted therapies for oncology and other unmet medical needs. The company is known for its lead product, FOTIVDA (tivozanib), an oral vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor used in the treatment of renal cell carcinoma (RCC). AVEO has completed a Phase III trial for tivozanib and is exploring its use in combination with the immune checkpoint inhibitor Opdivo. Additionally, the company is developing other therapeutic candidates, including Ficlatuzumab, an antibody for various cancers, and AV-203, a monoclonal antibody for esophageal cancer, which has completed Phase I trials. AVEO's preclinical pipeline includes promising products aimed at treating conditions such as cachexia and pulmonary arterial hypertension. Headquartered in Boston, Massachusetts, the company was founded in 2001 and has established collaborations with various pharmaceutical firms to enhance its development efforts.

Digit Wireless, operates as a user interface innovation company. It offers Fastap keypad technology solutions that enable to discover, access, and use messaging, mobile data, and voice services. The company licenses its technology to mobile manufacturers and operators. Digit Wireless, Inc. was founded in 2000 and is headquartered in Burlington, Massachusetts with additional offices in Beijing, Shanghai, Hong Kong, London, and Seoul.

Intarcia Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for chronic conditions requiring long-term treatment. The company is known for its innovative drug delivery platform, DUROS, which stabilizes and administers therapeutic proteins and peptides effectively. Among its key products is ITCA 650, currently in phase 3 clinical trials for type 2 diabetes, designed to provide patients with continuous dosing of an incretin mimetic therapy. Intarcia also explores treatments for obesity and other chronic disorders. Established in 1995 and headquartered in Boston, Massachusetts, Intarcia operates a manufacturing facility in Hayward, California, and a research and development center in Durham, North Carolina. The company was previously known as BioMedicines, Inc. before adopting its current name in 2004.

Ironwood Pharmaceuticals is a specialty pharmaceutical company focused on gastroenterology therapies. Its lead product is linaclotide, marketed as LINZESS in the United States and CONSTELLA elsewhere, for adults with irritable bowel syndrome with constipation and chronic idiopathic constipation. The company is advancing other GI candidates, including MD-7246, an oral non-opioid pain reliever for abdominal GI pain, and IW 3718, a gastric-retentive bile acid sequestrant in Phase III for GERD. Ironwood pursues collaborations to expand linaclotide’s reach in North America, China, Hong Kong, Macau, and Japan, with agreements involving Allergan and AstraZeneca and a license with Astellas for Japan. It operates an independent subsidiary, Microbia, that develops bioprocesses for pharmaceuticals and related industries. Founded in 1998, Ironwood is headquartered in Massachusetts.

Veridiem Inc is an enterprise software company based in Maynard, Massachusetts, specializing in marketing resource management solutions. The company provides a comprehensive suite of applications focused on marketing analysis, operational efficiency, and optimization tailored for the automotive, consumer packaged goods, and financial industries. In addition to its software offerings, Veridiem also delivers implementation, professional, training, and support services to ensure effective utilization of its solutions.

Authentica is a software company that provides content security solutions to protect and control business information. It offers enterprise rights management to control, secure, and track information, with secure delivery and after-delivery protection for email, electronic documents, and web content. Founded in 1998, Authentica is headquartered in Lexington, Massachusetts.

AVEO Oncology is a biopharmaceutical company that specializes in developing and commercializing targeted therapies for oncology and other unmet medical needs. The company is known for its lead product, FOTIVDA (tivozanib), an oral vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor used in the treatment of renal cell carcinoma (RCC). AVEO has completed a Phase III trial for tivozanib and is exploring its use in combination with the immune checkpoint inhibitor Opdivo. Additionally, the company is developing other therapeutic candidates, including Ficlatuzumab, an antibody for various cancers, and AV-203, a monoclonal antibody for esophageal cancer, which has completed Phase I trials. AVEO's preclinical pipeline includes promising products aimed at treating conditions such as cachexia and pulmonary arterial hypertension. Headquartered in Boston, Massachusetts, the company was founded in 2001 and has established collaborations with various pharmaceutical firms to enhance its development efforts.

ProfitLogic is a company specializing in the development and marketing of retail profit optimization software solutions. Established in 1983 and based in Cambridge, Massachusetts, it provides a comprehensive suite of applications designed to assist retailers in making informed decisions regarding allocation, planning, pricing, and inventory management. Its offerings encompass various aspects of retail operations, including assortment and allocation, pricing strategies, promotions and marketing, as well as performance assessment and management. Through its innovative software solutions, ProfitLogic aims to enhance profitability across all retail verticals. The company was previously known as Technology Strategy, Inc. (TSI).

Founded in 1997 and headquartered in Wellesley, Massachusetts, Coley Pharmaceutical Group is a biopharmaceutical company focused on developing therapeutics that harness the human immune system to combat cancers, asthma and allergy, autoimmune disorders, and enhance vaccine effectiveness. The company's platform specializes in vaccine adjuvant technology and immunomodulatory drug candidates.

Intarcia Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for chronic conditions requiring long-term treatment. The company is known for its innovative drug delivery platform, DUROS, which stabilizes and administers therapeutic proteins and peptides effectively. Among its key products is ITCA 650, currently in phase 3 clinical trials for type 2 diabetes, designed to provide patients with continuous dosing of an incretin mimetic therapy. Intarcia also explores treatments for obesity and other chronic disorders. Established in 1995 and headquartered in Boston, Massachusetts, Intarcia operates a manufacturing facility in Hayward, California, and a research and development center in Durham, North Carolina. The company was previously known as BioMedicines, Inc. before adopting its current name in 2004.

Authentica is a software company that provides content security solutions to protect and control business information. It offers enterprise rights management to control, secure, and track information, with secure delivery and after-delivery protection for email, electronic documents, and web content. Founded in 1998, Authentica is headquartered in Lexington, Massachusetts.

AVEO Oncology is a biopharmaceutical company that specializes in developing and commercializing targeted therapies for oncology and other unmet medical needs. The company is known for its lead product, FOTIVDA (tivozanib), an oral vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor used in the treatment of renal cell carcinoma (RCC). AVEO has completed a Phase III trial for tivozanib and is exploring its use in combination with the immune checkpoint inhibitor Opdivo. Additionally, the company is developing other therapeutic candidates, including Ficlatuzumab, an antibody for various cancers, and AV-203, a monoclonal antibody for esophageal cancer, which has completed Phase I trials. AVEO's preclinical pipeline includes promising products aimed at treating conditions such as cachexia and pulmonary arterial hypertension. Headquartered in Boston, Massachusetts, the company was founded in 2001 and has established collaborations with various pharmaceutical firms to enhance its development efforts.

Ironwood Pharmaceuticals is a specialty pharmaceutical company focused on gastroenterology therapies. Its lead product is linaclotide, marketed as LINZESS in the United States and CONSTELLA elsewhere, for adults with irritable bowel syndrome with constipation and chronic idiopathic constipation. The company is advancing other GI candidates, including MD-7246, an oral non-opioid pain reliever for abdominal GI pain, and IW 3718, a gastric-retentive bile acid sequestrant in Phase III for GERD. Ironwood pursues collaborations to expand linaclotide’s reach in North America, China, Hong Kong, Macau, and Japan, with agreements involving Allergan and AstraZeneca and a license with Astellas for Japan. It operates an independent subsidiary, Microbia, that develops bioprocesses for pharmaceuticals and related industries. Founded in 1998, Ironwood is headquartered in Massachusetts.

Cedar Point Communications specializes in integrated voice over Internet Protocol (VoIP) and multimedia switching technologies tailored for the telecommunications industry, both for service providers and enterprises. The company's key offerings include SAFARI C3, a media switching system that facilitates the transition to Internet Protocol Multimedia Subsystem (IMS) architecture for converged networks, and SAFARI eMG, a flexible media gateway. In addition to its product suite, Cedar Point Communications provides training and comprehensive customer support services. The company caters to a diverse clientele, including information technology departments, network operators, cable operators, telecommunications carriers, enterprise customers, and educational institutions. Founded in 2000, Cedar Point Communications is headquartered in Derry, New Hampshire, with an additional office located in Meersburg, Germany.

Kenet, Inc. is a fabless semiconductor company specializing in the development of CMOS analog-to-digital converters. Its products find applications in various fields, including oscilloscopes, USB oscilloscopes, digitizers, spectrum analyzers, and software-defined radios, among others. Founded in 2002 and headquartered in Woburn, Massachusetts, Kenet operates through distributors located in Mansfield, Texas, and LaFox, Illinois. The company's technology is integral to processes such as IF sampling, direct conversion, and digital predistortion, serving sectors that demand high-performance signal processing. Since 2008, Kenet has functioned as a subsidiary of Intersil Corp.

DataPower Technology offers solutions for processing extensible mark-up language (XML) that provides a format for structuring data. It offers XML Generation Three, a technology for processing XML in wire speed XML network devices that enable high-speed applications and XML Web services. The company provides XML-aware network devices that address the performance, security, and manageability. The company was founded in 1999 and is headquartered in Cambridge, Massachusetts.

Ironwood Pharmaceuticals is a specialty pharmaceutical company focused on gastroenterology therapies. Its lead product is linaclotide, marketed as LINZESS in the United States and CONSTELLA elsewhere, for adults with irritable bowel syndrome with constipation and chronic idiopathic constipation. The company is advancing other GI candidates, including MD-7246, an oral non-opioid pain reliever for abdominal GI pain, and IW 3718, a gastric-retentive bile acid sequestrant in Phase III for GERD. Ironwood pursues collaborations to expand linaclotide’s reach in North America, China, Hong Kong, Macau, and Japan, with agreements involving Allergan and AstraZeneca and a license with Astellas for Japan. It operates an independent subsidiary, Microbia, that develops bioprocesses for pharmaceuticals and related industries. Founded in 1998, Ironwood is headquartered in Massachusetts.

Onex Communications is a telecommunications equipment provider based in Bedford, Massachusetts, specializing in advanced VLSI solutions for converged communications networks. The company offers innovative products, including its System Silicon, which enables telecom equipment vendors to enhance their offerings with integrated switching, routing, and transmission capabilities. This technology provides a flexible migration path for existing products, allowing emerging vendors to develop cutting-edge systems while significantly reducing costs, power consumption, and space requirements. Onex Communications focuses on enabling service providers to achieve operational efficiency through simplified provisioning and decreased inventory costs. The company collaborates with industry leaders, including IBM and TranSwitch Corporation, to ensure the delivery of best-in-class solutions that help clients optimize their processes and adapt to next-generation requirements in an increasingly competitive telecommunications marketplace.

eYak (Sonexis) is an IP telephony services company. It provides internet protocol media server software and solutions for voice applications. The company was founded by Jeff Flowers in 1999 and is headquartered in Boston, Massachusetts.

Tilion is a company based in Maynard, Massachusetts, founded in 2000 by Chris Stone. It specializes in providing infrastructure and data services to online businesses. The company aggregates e-commerce data from supply-chain transactions, which it then organizes and presents in a user-friendly, printable report format. Tilion's focus on infrastructure services supports its clients in making informed decisions based on comprehensive data analysis.

Veridiem Inc is an enterprise software company based in Maynard, Massachusetts, specializing in marketing resource management solutions. The company provides a comprehensive suite of applications focused on marketing analysis, operational efficiency, and optimization tailored for the automotive, consumer packaged goods, and financial industries. In addition to its software offerings, Veridiem also delivers implementation, professional, training, and support services to ensure effective utilization of its solutions.

Syntonix Pharmaceuticals is a biopharmaceutical company based in Waltham, Massachusetts, specializing in the discovery and development of novel, long-acting therapeutic products for chronic diseases like hemophilia, anemia, and autoimmune disorders. The company utilizes proprietary Fc-fusion proteins and engineered ligands to enhance drug delivery and efficacy. Syntonix focuses on developing selected products independently while partnering with established companies for others. With a team of experienced professionals, Syntonix aims to improve existing drugs by leveraging its innovative technology. The company operates out of a state-of-the-art 25,000 square foot laboratory facility, including a cGMP clinical manufacturing suite.

Ironwood Pharmaceuticals is a specialty pharmaceutical company focused on gastroenterology therapies. Its lead product is linaclotide, marketed as LINZESS in the United States and CONSTELLA elsewhere, for adults with irritable bowel syndrome with constipation and chronic idiopathic constipation. The company is advancing other GI candidates, including MD-7246, an oral non-opioid pain reliever for abdominal GI pain, and IW 3718, a gastric-retentive bile acid sequestrant in Phase III for GERD. Ironwood pursues collaborations to expand linaclotide’s reach in North America, China, Hong Kong, Macau, and Japan, with agreements involving Allergan and AstraZeneca and a license with Astellas for Japan. It operates an independent subsidiary, Microbia, that develops bioprocesses for pharmaceuticals and related industries. Founded in 1998, Ironwood is headquartered in Massachusetts.

Veridiem Inc is an enterprise software company based in Maynard, Massachusetts, specializing in marketing resource management solutions. The company provides a comprehensive suite of applications focused on marketing analysis, operational efficiency, and optimization tailored for the automotive, consumer packaged goods, and financial industries. In addition to its software offerings, Veridiem also delivers implementation, professional, training, and support services to ensure effective utilization of its solutions.

Castle Networks provides carrier-class telecommunications equipment to facilitate data and voice convergence. The company was founded in 1998 and based in Westford, Massachusetts.

Caliper Life Sciences, Inc. is a provider of products and services tailored for pharmaceutical and biotechnology companies, as well as government and nonprofit research institutions. The company specializes in integrated systems that encompass instruments, software, reagents, and laboratory automation tools, aimed at enhancing the drug discovery and development process. Its offerings include advanced technologies for molecular imaging, microfluidics, and liquid handling, which address critical challenges in research. Notable products include IVIS Imaging Systems for optical molecular imaging, LabChip systems for drug discovery that enhance data accuracy, and automated liquid handling instruments such as the Caliper Sciclone. Additionally, Caliper provides contract research services, transgenic animal services, and comprehensive support for drug discovery. Founded in 1995 and headquartered in Hopkinton, Massachusetts, Caliper Life Sciences sells its products through a dedicated sales force and a network of distributors, helping researchers streamline their workflows and improve the efficiency of preclinical studies.

ThermoSpectra develops, manufactures, and markets precision imaging, inspection, and measurement instrumentation that uses high-speed data acquisition and digital processing technologies. The company is based in Franklin, Massachusetts.

Millennium Pharmaceuticals is a biopharmaceutical company focused on the research, development, and commercialization of cancer treatments. Established in 1993 and headquartered in Cambridge, Massachusetts, the company operates facilities in San Diego, San Francisco, Tsukuba, and Osaka. Millennium is known for developing VELCADE, an injectable therapy used for patients with multiple myeloma and relapsed mantle cell lymphoma. As of 2008, it has functioned as a subsidiary of Takeda Pharmaceutical Company, enhancing its capabilities and reach in the global market for oncology medications.

PerSeptive Biosystems develops instrumentation systems and consumable products for the purification, analysis, and synthesis of biomolecules. It develops and markets instrument-based systems, reagents, software, and contract services to the life science industry and research community. Customers of PerSeptive Biosystems use these tools to analyze nucleic acids (DNA and RNA) and proteins in order to make scientific discoveries, develop new pharmaceuticals, and conduct standardized testing. Founded in 1989, PerSeptive Biosystems is based in Framingham, Massachusetts. Currently, it operates as a subsidiary of Life Technologies Corporation.

Mitek Surgical Products provided bone anchors and minimally invasive surgical tools for orthopedic surgery. The company was founded by three Massachusetts Institute of Technology engineers in 1985.

Sunovion Pharmaceuticals Inc. is a biopharmaceutical company based in Marlborough, Massachusetts, dedicated to the development and commercialization of innovative therapeutic products for patients with central nervous system disorders, respiratory conditions, and other serious illnesses. The company offers a range of medications, including those for insomnia, schizophrenia, bipolar depression, epilepsy, asthma, and chronic obstructive pulmonary disease. Notable products include LUNESTA for sleep disorders, LATUDA for schizophrenia, and various inhalation solutions for respiratory issues. Sunovion's pipeline includes promising treatments such as Apomorphine Sublingual Film for Parkinson's disease and Lonhala Magnair for COPD. Founded in 1984 and formerly known as Sepracor, Sunovion operates as a subsidiary of Sumitomo Dainippon Pharma America, Inc. and is committed to enhancing patient care through ongoing research and development.

IDEXX Laboratories, Inc. specializes in developing, manufacturing, and distributing diagnostic products and services for the companion animal, livestock, poultry, dairy, and water testing markets globally. The company operates through several segments, including Companion Animal Group, Water Quality Products, Livestock, Poultry, and Dairy, among others. IDEXX offers a wide range of point-of-care veterinary diagnostic tools, instruments, and rapid assay test kits, as well as reference laboratory services and practice management software for veterinarians. Additionally, the company provides diagnostic tests for livestock and poultry health management and water quality testing to ensure safety. IDEXX's products enhance veterinary care capabilities, improve operational efficiency, and support the economic success of veterinary practices. With over 4,900 employees, IDEXX Laboratories serves customers in more than 100 countries and generates a significant portion of its revenue from international markets. The company is headquartered in Westbrook, Maine.

Cognex designs, develops, and markets machine vision products that automate manufacturing and distribution. It offers VisionPro software, Cognex Designer, and deep learning vision software, along with general-purpose vision systems such as In-Sight and a range of vision sensors. The company also provides ID products, including DataMan barcode readers and barcode verifiers. Cognex serves industries such as consumer electronics, automotive, consumer products, food and beverage, pharmaceuticals, and medical devices, selling through distributors and system integrators. Founded in 1981, Cognex is headquartered in Natick, Massachusetts.

Apollo Computer develops and markets workstation class computers and instruments. In 1996 the company ceased to exist after its employees were relocated, or offered other jobs within the HP family. Apollo would be later merged into the workstations group located in Colorado. The company is based in Chelmsford, Massachusetts.